129 related articles for article (PubMed ID: 22394161)
1. Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma.
Patel SP; Kim KB
Expert Opin Investig Drugs; 2012 Apr; 21(4):531-9. PubMed ID: 22394161
[TBL] [Abstract][Full Text] [Related]
2. Selumetinib for the treatment of cancer.
Ciombor KK; Bekaii-Saab T
Expert Opin Investig Drugs; 2015 Jan; 24(1):111-123. PubMed ID: 25385055
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma.
Catalanotti F; Solit DB; Pulitzer MP; Berger MF; Scott SN; Iyriboz T; Lacouture ME; Panageas KS; Wolchok JD; Carvajal RD; Schwartz GK; Rosen N; Chapman PB
Clin Cancer Res; 2013 Apr; 19(8):2257-64. PubMed ID: 23444215
[TBL] [Abstract][Full Text] [Related]
4. Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT).
Carvajal RD; Schwartz GK; Mann H; Smith I; Nathan PD
BMC Cancer; 2015 Jun; 15():467. PubMed ID: 26059332
[TBL] [Abstract][Full Text] [Related]
5. Treating non-small cell lung cancer with selumetinib: an up-to-date drug evaluation.
Imyanitov EN; Levchenko EV; Kuligina ES; Orlov SV
Expert Opin Pharmacother; 2020 Nov; 21(16):1943-1953. PubMed ID: 32880495
[TBL] [Abstract][Full Text] [Related]
6. Trametinib (GSK1120212) in the treatment of melanoma.
Salama AK; Kim KB
Expert Opin Pharmacother; 2013 Apr; 14(5):619-27. PubMed ID: 23432625
[TBL] [Abstract][Full Text] [Related]
7. A prolonged complete response in a patient with BRAF-mutated melanoma stage IV treated with the MEK1/2 inhibitor selumetinib (AZD6244).
Boers-Sonderen MJ; Desar IM; Blokx W; Timmer-Bonte JN; van Herpen CM
Anticancer Drugs; 2012 Aug; 23(7):761-4. PubMed ID: 22293660
[TBL] [Abstract][Full Text] [Related]
8. The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models.
Holt SV; Logié A; Odedra R; Heier A; Heaton SP; Alferez D; Davies BR; Wilkinson RW; Smith PD
Br J Cancer; 2012 Feb; 106(5):858-66. PubMed ID: 22343622
[TBL] [Abstract][Full Text] [Related]
9. Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244).
Dry JR; Pavey S; Pratilas CA; Harbron C; Runswick S; Hodgson D; Chresta C; McCormack R; Byrne N; Cockerill M; Graham A; Beran G; Cassidy A; Haggerty C; Brown H; Ellison G; Dering J; Taylor BS; Stark M; Bonazzi V; Ravishankar S; Packer L; Xing F; Solit DB; Finn RS; Rosen N; Hayward NK; French T; Smith PD
Cancer Res; 2010 Mar; 70(6):2264-73. PubMed ID: 20215513
[TBL] [Abstract][Full Text] [Related]
10. Selumetinib Inhibits Melanoma Metastasis to Mouse Liver
Ryu SH; Heo SH; Park EY; Choi KC; Ryu JW; Lee SH; Lee SW
Anticancer Res; 2017 Feb; 37(2):607-614. PubMed ID: 28179307
[TBL] [Abstract][Full Text] [Related]
11. Activity of the MEK inhibitor selumetinib (AZD6244; ARRY-142886) in nasopharyngeal cancer cell lines.
Ma BB; Lui VW; Cheung CS; Lau CP; Ho K; Hui EP; Tsui SK; Ng MH; Cheng SH; Ng PK; Tsao SW; Chan AT
Invest New Drugs; 2013 Feb; 31(1):30-8. PubMed ID: 22565394
[TBL] [Abstract][Full Text] [Related]
12. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.
Ho AL; Grewal RK; Leboeuf R; Sherman EJ; Pfister DG; Deandreis D; Pentlow KS; Zanzonico PB; Haque S; Gavane S; Ghossein RA; Ricarte-Filho JC; Domínguez JM; Shen R; Tuttle RM; Larson SM; Fagin JA
N Engl J Med; 2013 Feb; 368(7):623-32. PubMed ID: 23406027
[TBL] [Abstract][Full Text] [Related]
13. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor.
Yeh TC; Marsh V; Bernat BA; Ballard J; Colwell H; Evans RJ; Parry J; Smith D; Brandhuber BJ; Gross S; Marlow A; Hurley B; Lyssikatos J; Lee PA; Winkler JD; Koch K; Wallace E
Clin Cancer Res; 2007 Mar; 13(5):1576-83. PubMed ID: 17332304
[TBL] [Abstract][Full Text] [Related]
14. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins.
Friday BB; Yu C; Dy GK; Smith PD; Wang L; Thibodeau SN; Adjei AA
Cancer Res; 2008 Aug; 68(15):6145-53. PubMed ID: 18676837
[TBL] [Abstract][Full Text] [Related]
15. Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI.
Beloueche-Babari M; Jamin Y; Arunan V; Walker-Samuel S; Revill M; Smith PD; Halliday J; Waterton JC; Barjat H; Workman P; Leach MO; Robinson SP
Br J Cancer; 2013 Sep; 109(6):1562-9. PubMed ID: 23942066
[TBL] [Abstract][Full Text] [Related]
16. Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886).
Balagula Y; Barth Huston K; Busam KJ; Lacouture ME; Chapman PB; Myskowski PL
Invest New Drugs; 2011 Oct; 29(5):1114-21. PubMed ID: 20978926
[TBL] [Abstract][Full Text] [Related]
17. Targeting the mitogen‑activated protein kinase kinase and protein kinase A pathways overcomes acquired resistance to Selumetinib in low‑grade glioma cells.
Melotti L; Meco D; Battaglia A; Buzzonetti A; Martini M; Ruggiero A; Scambia G; Riccardi R
Oncol Rep; 2021 Feb; 45(2):752-763. PubMed ID: 33416182
[TBL] [Abstract][Full Text] [Related]
18. Binimetinib for the treatment of NRAS-mutant melanoma.
Queirolo P; Spagnolo F
Expert Rev Anticancer Ther; 2017 Nov; 17(11):985-990. PubMed ID: 28851243
[TBL] [Abstract][Full Text] [Related]
19. Selumetinib: a selective MEK1 inhibitor for solid tumor treatment.
Hedayat M; Jafari R; Majidi Zolbanin N
Clin Exp Med; 2023 Jun; 23(2):229-244. PubMed ID: 35171389
[TBL] [Abstract][Full Text] [Related]
20. Mitogen-activated protein/extracellular signal-regulated kinase kinase inhibition results in biphasic alteration of epidermal homeostasis with keratinocytic apoptosis and pigmentation disorders.
Schad K; Baumann Conzett K; Zipser MC; Enderlin V; Kamarashev J; French LE; Dummer R
Clin Cancer Res; 2010 Feb; 16(3):1058-64. PubMed ID: 20103661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]